Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial.

Kohei Shitara, Takayuki Yoshino, Hisatsugu Ohori et al.|Journal of Clinical Oncology|2023

Cited by 35